Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections | Zendy

Laura Clark | Zendy; Bruce E. Silverstein | Zendy; Timothy W. Morris | Zendy; Lynne S. Gearinger | Zendy; Timothy L. Comstock | Zendy; Heleen H. DeCory | Zendy

Open Access

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections

Author(s) -

Laura Clark,

Bruce E. Silverstein,

Timothy W. Morris,

Lynne S. Gearinger,

Timothy L. Comstock,

Heleen H. DeCory

Publication year - 2012

Publication title -

clinical ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 56

eISSN - 1177-5483

pISSN - 1177-5467

DOI - 10.2147/opth.s35715

Subject(s) - medicine , bacterial conjunctivitis , pseudomonas aeruginosa , visual acuity , clinical trial , microbiological culture , incidence (geometry) , adverse effect , ophthalmology , antibiotics , microbiology and biotechnology , bacteria , genetics , physics , optics , biology

The purpose of this study was to determine the efficacy of besifloxacin ophthalmic suspension 0.6% when used in the treatment of bacterial conjunctivitis infections due to Pseudomonas aeruginosa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research